- Home
- GYRE vs SA Comparison
GYRE vs SA Comparison
Compare GYRE & SA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- SA
- Stock Information
- Founded
- GYRE 2002
- SA 1979
- Country
- GYRE United States
- SA Canada
- Employees
- GYRE N/A
- SA N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- SA Precious Metals
- Sector
- GYRE Health Care
- SA Basic Materials
- Exchange
- GYRE Nasdaq
- SA Nasdaq
- Market Cap
- GYRE 897.1M
- SA 1.0B
- IPO Year
- GYRE N/A
- SA N/A
- Fundamental
- Price
- GYRE $9.53
- SA $12.62
- Analyst Decision
- GYRE
- SA
- Analyst Count
- GYRE 0
- SA 0
- Target Price
- GYRE N/A
- SA N/A
- AVG Volume (30 Days)
- GYRE 105.9K
- SA 720.3K
- Earning Date
- GYRE 05-09-2025
- SA 05-20-2025
- Dividend Yield
- GYRE N/A
- SA N/A
- EPS Growth
- GYRE N/A
- SA N/A
- EPS
- GYRE 0.04
- SA N/A
- Revenue
- GYRE $100,643,000.00
- SA N/A
- Revenue This Year
- GYRE $22.01
- SA N/A
- Revenue Next Year
- GYRE $88.14
- SA N/A
- P/E Ratio
- GYRE $213.36
- SA N/A
- Revenue Growth
- GYRE N/A
- SA N/A
- 52 Week Low
- GYRE $6.11
- SA $9.40
- 52 Week High
- GYRE $19.00
- SA $20.55
- Technical
- Relative Strength Index (RSI)
- GYRE 55.67
- SA 55.76
- Support Level
- GYRE $8.51
- SA $12.19
- Resistance Level
- GYRE $9.98
- SA $13.05
- Average True Range (ATR)
- GYRE 0.61
- SA 0.43
- MACD
- GYRE 0.10
- SA -0.00
- Stochastic Oscillator
- GYRE 73.84
- SA 65.87
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.